
Novo Biosciences: Innovating cardiac drugs and cancer treatments for life-saving care.
Novo Biosciences, founded with a mission to develop innovative cardiac drugs and cancer treatments, aims to reverse life-threatening damage caused by heart attacks and improve cancer care. The company's core vision is to provide life-saving medical solutions through advanced drug development. Novo Biosciences focuses on creating therapies that address critical health conditions, particularly in the cardiovascular and oncology sectors.
Notable affiliated individuals and investors include leading scientists and venture capital firms specializing in biotechnology. Novo Biosciences has achieved significant milestones in preclinical and clinical trials, demonstrating the efficacy of its cardiac drugs. The company's impact is marked by its potential to transform treatment paradigms for heart attack recovery and cancer therapy, contributing to improved patient outcomes and advancing medical science.

NovoMedix
novomedix.com

Novita Pharmaceuticals
novita-pharm.com

Novoron Bioscience
novoron.com

Cardurion Pharmaceuticals

Nexo Therapeutics
nexotx.com
Accunovo Biotechnologies

NovoBiotic Pharmaceuticals
novobiotic.com

Denovo Biopharma

Nuovo Biologics
nuovobiologics.com

Ventrinova

Noveome Biotherapeutics
noveome.com

Nerx Biosciences

NeoProgen

Know Bio
knowbiollc.com

Bitterroot Bio
brbio.com
Companies similar to Novo Biosciences include NovoMedix, Novita Pharmaceuticals, Novoron Bioscience and Cardurion Pharmaceuticals.
Novo Biosciences was founded in 2013.
Novo Biosciences' headquarters is located in Bar Harbor, ME, US.
Novo Biosciences' most recent funding round was for $4M (USD) in May 2020.
As of May 28, 2020, Novo Biosciences has raised a total of $5.6M (USD).
Novo Biosciences has 6 employees as of Feb 5, 2024.